Cargando…

S220. BLONANSERIN AUGMENTATION IN PATIENTS WITH SCHIZOPHRENIA – WHO IS BENEFITED FROM BLONANSERIN AUGMENTATION? AN OPEN-LABEL, PROSPECTIVE, MULTI-CENTER STUDY

BACKGROUND: Evidences for antipsychotic augmentation for schizophrenic patients with sub-optimal efficacy have been lacking although it has been widespread therapeutic strategy in clinical practice. The purpose of this study was to investigate the efficacy and tolerability of blonanserin augmentatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bahk, Won-Myong, Kwon, Young Joon, Yoon, Bo-Hyun, Lee, Sang-Yeol, Lee, Kwanghun, Jon, Duk-In, Kim, Moon Doo, Lim, Eunsung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887360/ http://dx.doi.org/10.1093/schbul/sby018.1007

Ejemplares similares

Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2016)

PM423. Blonanserin augmentation in patients with schizophrenia – who is benefited from blonanserin augmentation?: An open-label, prospective, multicenter study
por: Woo, Young Sup, et al.
Publicado: (2016)

Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2019)

Profile of blonanserin for the treatment of schizophrenia
por: Tenjin, Tomomi, et al.
Publicado: (2013)

Early prediction of blonanserin response in Japanese patients with schizophrenia
por: Kishi, Taro, et al.
Publicado: (2014)

Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report
por: Sakai, Shintaro, et al.
Publicado: (2021)

Simple and Sensitive Analysis of Blonanserin and Blonanserin C in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry and Its Application
por: Zheng, Yunliang, et al.
Publicado: (2014)

Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Blonanserin-induced Mood Alteration in Schizophrenia and Schizoaffective Disorder: Two Cases
por: Min, Aran, et al.
Publicado: (2013)

A case of delusional parasitosis responded to blonanserin
por: Rathi, Anubhav, et al.
Publicado: (2018)

A case of schizophrenia with relapsed catatonia successfully treated with blonanserin transdermal patch
por: Hagikura, Minako, et al.
Publicado: (2023)

Prediction of Corresponding Dose of Transdermal Blonanserin to Oral Dose Based on Dopamine D(2) Receptor Occupancy: Unique Characteristics of Blonanserin Transdermal Patch
por: Tomita, Yoshiko, et al.
Publicado: (2022)

A Simple and Sensitive HPLC-MS/MS Assay for the Quantitation of Blonanserin and N-Desethyl Blonanserin in Rat Plasma and Its Application to Pharmacokinetic Study
por: Huang, Shan-qing, et al.
Publicado: (2022)

Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone
por: Hori, Hikaru, et al.
Publicado: (2014)

A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
por: Kishi, Taro, et al.
Publicado: (2016)

PM498. Investigation of feelings toward taking blonanserin and risperidone in schizophrenia patients: part 2
por: Shoji, Yoshihisa, et al.
Publicado: (2016)

Long-term oral blonanserin treatment for schizophrenia: a review of Japanese long-term studies
por: Murasaki, Mitsukuni, et al.
Publicado: (2021)

Blonanserin treatment in patients with methamphetamine-induced psychosis comorbid with intellectual disabilities
por: Okazaki, Kosuke, et al.
Publicado: (2016)

Evaluation of dopamine D(3) receptor occupancy by blonanserin using [(11)C]-(+)-PHNO in schizophrenia patients
por: Sakayori, Takeshi, et al.
Publicado: (2020)

T219. THE ROLE OF MELATONIN AND MELATONIN AGONISTS IN COUNTERACTING ANTIPSYCHOTIC-INDUCED METABOLIC SIDE EFFECTS: A SYSTEMATIC REVIEW
por: Bahk, Won-Myong, et al.
Publicado: (2018)

Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study
por: Iwata, Nakao, et al.
Publicado: (2019)

Long-Term Safety and Efficacy of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 52-Week, Multicenter, Open-Label Extension Study
por: Saito, Takuya, et al.
Publicado: (2022)

Cardiometabolic Risks of Blonanserin and Perospirone in the Management of Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Kishi, Taro, et al.
Publicado: (2014)

One-Year Follow-Up of Serum Prolactin Level in Schizophrenia Patients Treated with Blonanserin: A Case Series
por: Takahashi, Sakae, et al.
Publicado: (2015)

Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study
por: Saito, Takuya, et al.
Publicado: (2022)

PM429. Comparison of haloperidol and blonanserin on development of dopamine supersensitivity after chronic treatment
por: Hashimoto, Takashi, et al.
Publicado: (2016)

Survival of Combined Overdose with Very High Doses of Clozapine and Blonanserin: A Case Report
por: Faisal, Mohammad, et al.
Publicado: (2022)

Effectiveness and safety of blonanserin in young and middle-aged female patients with schizophrenia: data from a post-marketing surveillance
por: Bo, Qijing, et al.
Publicado: (2023)

Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials
por: Deng, Shu-Wen, et al.
Publicado: (2023)

Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: An Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance
por: Wu, Haishan, et al.
Publicado: (2022)

Possible effect of blonanserin on gambling disorder: A clinical study protocol and a case report
por: Shiina, Akihiro, et al.
Publicado: (2021)

PM397. Effectiveness of blonanserin in patients with schizophrenia: A systematic review and meta-analysis of direct head-to-head comparisons with other antipsychotics
por: Kishi, T., et al.
Publicado: (2016)

Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8‐week, double‐blind, multicenter, randomized controlled study
por: Harvey, Philip D., et al.
Publicado: (2019)

The Influence of Blonanserin Supersaturation in Liquid and Silica Stabilised Self-Nanoemulsifying Drug Delivery Systems on In Vitro Solubilisation
por: Møller, Amalie, et al.
Publicado: (2023)

Striatal Dopamine D(2) Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia
por: Nishibe, Hironori, et al.
Publicado: (2020)

S196. ASSOCIATION BETWEEN INTRACELLULAR INFECTIOUS AGENTS AND SCHIZOPHRENIA IN KOREA
por: Kwon, Young-Joon, et al.
Publicado: (2018)

F213. THE EFFECTS OF GROUP INTEGRATIVE ARTS THERAPY BASED ON SOCIAL SKILL TRAINING ON THE SOCIAL ADAPTIVE FUNCTION, EMPOWERMENT AND SUBJECTIVE WELL-BEING IN INPATIENTS WITH CHRONIC SCHIZOPHRENIA
por: Lim, Eunsung, et al.
Publicado: (2018)

M46. THE STUDY OF HEART RATE VARIABILITY AND EMOTIONAL RESPONSE TO POSITIVE AND NEGATIVE AUDIOVISUAL STIMULATION IN PATIENTS WITH SCHIZOPHRENIA
por: Jang, Seung-Ho, et al.
Publicado: (2020)

M185. THE EFFECTS OF GROUP ARTS THERAPY BASED ON EMOTION MANAGEMENT TRAINING ON THE EMOTIONAL EXPRESSION, ALEXITHYMIA, DEPRESSION AND QUALITY OF LIFE IN PATIENTS WITH SCHIZOPHRENIA
por: Lim, Eunsung, et al.
Publicado: (2020)

F115. INSIGHT AND MANIC SYMPTOMS IN PATIENTS WITH CHRONIC SCHIZOPHRENIA IN THE KOREAN COMMUNITY
por: Jon, Duk-In, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fcfcisurviqcdj5s57hn93jg37